ImmunoGen, a US biopharmaceuticals company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug technology, says that its partner, Biogen Idec, has submitted an Investigational New Drug application for BIIB015.
The agent comprises ImmunoGen's cell-killing agent, DM4, linked to Biogen Idec's Cripto-targeting antibody, and is in development by the latter for the treatment of solid tumors that express the Cripto antigen. This triggers a $1.5 million milestone payment to the former.
Commenting on the move, Mitchel Sayare, chief executive of Immunogen, said: "we outlicense our TAP technology to other companies for use with their proprietary antibodies both for the financial return and to expand the number of compounds in development. We expect there to be as many as eight TAP compounds in the clinic by this summer - the five already in human clinical testing plus three more compounds advancing toward the clinic."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze